Sign Up Today and Learn More About ArriVent Biopharma Stock
Invest in or calculate the value of your shares in ArriVent Biopharma or other pre-IPO companies through EquityZen's platform.
ArriVent Biopharma Stock
ArriVent develops pharmaceutical products to cure presently untreatable cancer.
About ArriVent Biopharma Stock
Founded
2021
Headquarters
Pennsylvania Furnace, PA, US
Industries
Software, Artificial Intelligence, Data and Analytics
ArriVent Biopharma Press Mentions
Stay in the know about the latest news on ArriVent Biopharma
Cancer biotech ArriVent BioPharma prices upsized IPO at $18 midpoint
renaissancecapital • Feb 04, 2024
ArriVent Biopharma issues upsized $175M IPO, becomes region's first life sciences firm to go public in 2024
bizjournals • Feb 04, 2024
ArriVent Biopharma opens at $24, IPO priced at $18
thefly • Feb 03, 2024
Philly Money Moves: ArriVent Biopharma files for $100M IPO to develop potential lung cancer treatment
technical • Jan 28, 2024
Deal Watch: Cravath, Skadden, Shearman, K&L Gates Steer ...
law • Jan 20, 2024
ArriVent Biopharma Management
Leadership team at ArriVent Biopharma
SVP, Development Operations & Business Systems
Morgan Lam
CMO and Co-Founder
Stuart Lutzker
Join now and verify your accreditation status to gain access to:
- ArriVent Biopharma current valuation
- ArriVent Biopharma stock price
- Available deals in ArriVent Biopharma and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in ArriVent Biopharma stock?
Accredited investors can buy pre-IPO stock in companies like ArriVent Biopharma through EquityZen funds. These investments are made available by existing ArriVent Biopharma shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell ArriVent Biopharma stock?
Shareholders can sell their ArriVent Biopharma stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
